


Curriculum Vitae

Name	Melissa L Johnson, MD	
Current Position & Affiliation	Director, Lung Cancer Research Program Sarah Cannon- Tennessee Oncology	
Country	USA	

Educational Background

University of North Carolina—Chapel Hill, Chapel Hill, NC (8/1995-5/1999)
 University of Pennsylvania School of Medicine, Philadelphia, PA (8/2000-5/2004)
 New York Presbyterian/Weill Cornell Medical Center, New York, NY (6/2004-6/2007)
 Memorial Sloan Kettering Cancer Center, New York, NY (7/2007-6/2010)

Professional Experience

Assistant Professor, Robert H. Lurie Comprehensive Cancer Center/Northwestern University Feinberg School of Medicine (8/2010-10/2014)
 Associate Director, Lung Cancer Research, Sarah Cannon Research Institute (12/2014-present)
 Medical Oncologist, Tennessee Oncology, PLLC, Nashville, TN (1/2015-present)
 Physician, Tristar Centennial Medical Center, Nashville, TN (1/2015-present)

ADMINISTRATIVE APPOINTMENTS

Chief Fellow, Memorial Sloan Kettering Cancer Center (7/2008-6/2009)
 Grand Rounds Coordinator, RHLCCC/Northwestern University Feinberg School of Medicine (6/2011-6/2014)

Professional Organizations

UNIVERSITY OR HOSPITAL SERVICE

Data Safety Monitoring Board, Clinical Research Office, RHLCC/Northwestern University (1/2011-10/2014)

BEACOM Implementation Committee, Physician Representative, RHLCC/Northwestern University (5/2011-10/2014)

NMDTI/RHLCCC Integration Committee, Physician Representative, RHLCCC/Northwestern University (1/2014-10/2014)

NMDTI Path Core Optimization Committee, RHLCCC/Northwestern University (1/2014-10/2014)

Oncology Committee, Tristar Centennial Medical Center (1/2015-present, Chair 1/2018-present)

Credentials Committee, Tristar Centennial Medical Center (7/2015-present)

Sarah Cannon Cancer Center, Nashville Local Workgroup (1/2016-present)

NATIONAL COMMITTEES

Thoracic Core Committee, Eastern Cooperative Oncology Group (10/2010-10/2014)

Lung Cancer Expert Advisory Panel, American Lung Association of Metropolitan Chicago (10/2012-10/2014)

ASCO Cancer Research Committee (2013-2016)

ASCO Education Committee liaison from CRC (2014-2016)

ASCO Scientific Committee (2017-present, Chair, [Metastatic NSCLC Track, 2018; Scientific Program Chair, 2020](#))

HONORS AND AWARDS

Morehead-Cain Academic Scholarship (tuition, expenses, summer enrichment), University of North Carolina (1995-1999)

Bertha Dagan Berman Award for Women's Health (research fellowship), University of Pennsylvania (2003-2004)

Eileen Gong Weiner Award for Compassionate Care, New York Presbyterian/Weill Cornell Medical Center (2010)

ASCO Conquer Cancer Foundation Merit Award 2008

ASCO Conquer Cancer Foundation Merit Award 2009

Main Scientific Publications

1. Peters S, Gettinger S, **Johnson ML**, Jänne P, Garassino M, Christoph D, Keong T, Chee, Rizvi N, Chaft J, Carcereny Costa E, Patel JD, Chow L, Koczywas M, Ho C, Früh M, Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). *J Clin Oncol*. 2017 June. DOI: 10.1200/JCO.2016.71.9476
2. Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, **Johnson ML**, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Cuyun Carter G, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M. Outcomes in patients with aggressive or refractory disease from REVEL, a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. *Lung Cancer* 2017, accepted for publication.
3. [Lin JJ](#), [Zhu VW](#), [Yoda S](#), [Yeap BY](#), [Schrock AB](#), [Dagogo-Jack I](#), [Jessop NA](#), [Jiang GY](#), [Le LP](#), [Gowen K](#), [Stephens PJ](#), [Ross JS](#), [Ali SM](#), [Miller VA](#), **Johnson ML**, [Lovly CM](#), [Hata AN](#), [Gainor JF](#), [Iafrate AJ](#), [Shaw AT](#), [Ou SI](#). Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. *J Clin Oncol*. 2018 Jan 26;JCO2017762294. doi: 10.1200/JCO.2017.76.2294.
4. Bauer TM, Shaw AT, **Johnson ML**, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. *Targeted Oncology*. February 2020.
5. **Johnson ML**, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S. Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. *JAMA Oncol*. 2019 Jul 1;5(7):999-1007. doi: 10.1001/jamaoncol.2019.0836.
6. Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, **Johnson ML**, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. *JG.Cancer Discov*. 2020 Jan;10(1):54-

71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28. PMID: 31658955 Free PMC article.

7. Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, **Johnson ML**, Chung CH, Chen Y, Huang B, Davis CB, Toffalorio F, Thall A, Powell SF. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. *J ImmunoTherapy Cancer*. 2019 Dec. DOI: 10.1186/s40425-019-0815-6.

8. Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, **Johnson ML**, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. *Clin Cancer Res*. 2020 Mar 15;26(6):1220-1228. doi: 10.1158/1078-0432.CCR-19-2962. Epub 2019 Dec 3.

9. Papadopoulos KP, **Johnson ML**, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. *Clin Cancer Res*. 2019 Dec 3. doi: 10.1158/1078-0432.CCR-19-2609. [Epub ahead of print]

10. Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, Sudhakar N, Bowcut V, Baer BR, Ballard JA, Burkard MR, Fell JB, Fischer JP, Vigers GP, Xue Y, Gatto S, Fernandez-Banet J, Pavlicek A, Velastagui K, Chao RC, Barton J, Pierobon M, Baldelli E, Patricoin EF 3rd, Cassidy DP, Marx MA, Rybkin II, **Johnson ML**, Ou SI, Lito P, Papadopoulos KP, Jänne PA, Olson P, Christensen JG. The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. *Cancer Discov*. 2020 Jan;10(1):54-71. doi: 10.1158/2159-8290.CD-19-1167. Epub 2019 Oct 28.

11. Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, **Johnson ML**, Kimple RJ, Knoll MA, LoConte N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. *J Clin Oncol*. 2020 Apr 1;38(10):1081. doi: 10.1200/JCO.19.03141. Epub 2020 Feb 4.

12. Bauer TM, Shaw AT, **Johnson ML**, Navarro A, Gainor JF, Thurm H, Pithavala YK, Abbattista A, Peltz G, Felip E. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. *Target Oncol.* 2020 Feb;15(1):55-65. doi: 10.1007/s11523-020-00702-4.
13. Morgensztern D, **Johnson ML**, Rudin CM, Rossi M, Lazarov M, Brickman D, Fong A. Lung Cancer. SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. 2020 Jul;145:126-131. doi: 10.1016/j.lungcan.2020.04.017. Epub 2020 May 12.
14. Drilon A, Oxnard GR, Tan DSW, Loong HHF, **Johnson ML**, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med.* 2020 Aug; 383:813-824 DOI: 10.1056/NEJMoa2005653 Epub 2020 Aug 27.
15. Rosen EY, **Johnson ML**, Clifford SE, Somwar R, Kherani JF, Son J, Bertram AA, Davare MA, Gladstone E, Ivanova EV, Henry DN, Kelley EM, Lin M, Milan MSD, Nair BC, Olek EA, Scanlon JE, Vojnic M, Ebata K, Hechtman JF, Li BT, Sholl LM, Taylor BS, Ladanyi M, Jänne PA, Rothenberg SM, Drilon A, Oxnard GR. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. *Clin Cancer Res.* 2021 Jan 1;27(1):34-42. doi: 10.1158/1078-0432.CCR-20-2278. Epub 2020 Oct 20. PMID: 33082208
16. Patel JD, Lee JW, Carbone D, Wagner H, Shanker A, P. de Aquino MT, Horn L, **Johnson ML**, Gerber D, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). *Clinical Lung Cancer* 21: 2020.